DoW, Peer Reviewed Cancer, Impact Award | HT942526PRCRPIPA

FY26 PRCRP Impact Award (USAMRAA) - Frequently Asked Questions

What is the FY26 Peer Reviewed Cancer Research Program (PRCRP) Impact Award?

The FY26 PRCRP Impact Award is a U.S. Army Medical Research Acquisition Activity (USAMRAA) funding opportunity intended to support mature cancer research projects that are positioned to influence clinical care in the near term. The emphasis is on work that can credibly produce actionable, clinically relevant outcomes rather than early-stage discovery.

What is the main goal of this award mechanism?

The main goal is near-term impact in cancer, with deliverables framed in concrete terms such as clinically relevant findings, validated methods, or evidence that can inform patient care pathways and clinical decision-making, especially in ways that benefit the Military Health System (MHS).

How is this award different from early discovery or exploratory research funding?

This mechanism is aimed less at long-range exploratory aims and more at projects that are already well developed. Applications are expected to show a strong path to practical clinical utility and to be supported by preliminary data demonstrating feasibility.

Do projects need to align with specific PRCRP Topic Areas?

Yes. Proposed work is expected to fit within one of the congressionally directed FY26 PRCRP Topic Areas. Applicants should clearly connect their research to meaningful advances in cancer knowledge, patient care, and/or treatment options within those topic priorities.

How important is Military Health System (MHS) relevance?

MHS relevance is a key emphasis. Applicants are expected to connect their proposed research to benefits for the Military Health System, and to describe how outcomes could matter for clinical care and patient impact in that context.

Is preliminary data required?

Yes. A central requirement is that applications include preliminary data that demonstrate feasibility. Reviewers will look for evidence that the approach is technically sound and that the team can execute the work.

What will reviewers likely focus on when assessing applications?

Based on the opportunity description, reviewers will be looking for feasibility supported by preliminary data, technical soundness of the approach, the team’s ability to execute, and a strong likelihood that results will matter for clinical decision-making or patient outcomes in the near term.

What does "near-term impact" mean in practice for this program?

Near-term impact means the application should describe realistic, concrete deliverables that could influence clinical care soon. Examples mentioned or implied include clinically relevant findings, validated methods, or evidence that can inform care pathways, rather than speculative or distant future applications.

Are clinical trials allowed under this funding opportunity?

Yes. Unlike some mechanisms that exclude interventional studies, this opportunity explicitly allows clinical trials. This can include clinical evaluation of interventions, diagnostics, treatment strategies, or other patient-facing advances, as long as the work aligns with the topic areas and is supported by prior evidence showing readiness.

If proposing a clinical trial, what expectations are implied?

Because clinical trials are complex, the opportunity language implies that trial-related activities should be well justified, ethically and operationally feasible, and designed to generate clinically meaningful results. Readiness should be supported by prior evidence (including preliminary data).

What leadership structures are available for applying?

The program supports two leadership structures: (1) a single Principal Investigator (PI) model, or (2) a partnering PI arrangement involving an Initiating PI and a Partnering PI.

How does the partnering PI model work at the pre-application stage?

In the partnering PI model, only the Initiating PI submits the pre-application. The Partnering PI does not submit the pre-application based on the details provided.

What happens at the full application stage for a partnering PI submission?

Both the Initiating PI and the Partnering PI must submit full applications later. The Partnering PI submits an abbreviated application that covers their distinct portion of the overall research plan, while the full project is treated as a linked effort.

Are the Initiating PI and Partnering PI applications linked administratively?

Yes. The two applications are linked. If either the initiating or partnering application is rejected or administratively withdrawn, both applications for that project may be withdrawn. This makes coordination and compliance across both applications especially important.

What does it mean that the award is a discretionary grant?

The listing identifies the Funding Instrument Type as a Grant and describes it as discretionary, meaning it is a competitive assistance award made at the agency’s discretion under the program’s rules and review process.

What is the CFDA number for this opportunity?

The CFDA number provided is 12.420.

Which agency is offering this funding opportunity?

The agency is the Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What is the funding opportunity number?

The funding opportunity number is HT942526PRCRPIPA.

When was this opportunity posted, and what is the closing date?

The posting/creation date is May 6, 2026. The original closing date is October 5, 2026.

How many awards are expected?

The notice indicates an expectation of around 30 awards.

Is there an award ceiling or budget limit stated in the provided information?

No. The award ceiling is not specified in the provided text. Applicants would need to consult the full program announcement for budget limits and other financial constraints.

Who is eligible to apply?

Eligibility is listed as unrestricted in the opportunity listing details. That suggests a broad range of applicants may be allowed, but the full program announcement would still control the exact eligibility rules and requirements.

What activity category does this opportunity fall under?

It is listed within the Science and Technology and other Research and Development activity category.

What types of projects are a good fit for the PRCRP Impact Award?

Projects that already have strong supporting data, a well-defined plan, and a credible path to near-term clinical relevance are a good fit. The opportunity description points to work that can deliver actionable outcomes likely to influence clinical decision-making or patient outcomes, with alignment to FY26 PRCRP Topic Areas and relevance to the MHS.

What should applicants emphasize when describing outcomes and deliverables?

Applicants are expected to emphasize concrete, clinically meaningful outputs such as clinically relevant findings, validated methods, or evidence that could inform care pathways. The narrative should clearly link the proposed research to meaningful advances in cancer knowledge, patient care, and/or treatment options.